| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.097 | 0.004 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.21 | 0.008 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.092 | 0.009 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.67 | 0.009 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |